|
US2020155456A1
|
|
Use of higher doses of modified release huperzine formulations
|
|
CA3022339A1
|
|
Methods, system, and kit for monitoring, diagnosing, and treating impulsive aggression
|
|
WO2014078394A1
|
|
Method of treatment of aggression
|
|
US2014037745A1
|
|
Controlled release compositions of gamma-hydroxybutyrate
|
|
EP3290403A2
|
|
Methods of producing molindone and its salts
|
|
WO2013119794A1
|
|
Modified release formulations of viloxazine
|
|
AU2013200237A1
|
|
Controlled released preparations of oxcarbazepine having sigmoidal release profile
|
|
AU2011240773A1
|
|
Methods for producing viloxazine salts and novel polymorphs thereof
|
|
WO2011123497A1
|
|
Stabilized formulations of cns compounds
|
|
AU2011235221A1
|
|
Formulations of mazindol
|
|
AU2010326016A1
|
|
Method of treatment of CNS disorders
|
|
AU2010266285A1
|
|
A method of treatment of a neurological disorder
|
|
CA2760527A1
|
|
Method of treatment of depression
|
|
WO2010090991A1
|
|
Formulations of desvenlafaxine
|
|
AU2009335709A1
|
|
Method of treatment of aggression
|
|
EP2341912A2
|
|
Method of treatment of attention deficit/hyperactivity disorder (adhd)
|
|
CA2725482A1
|
|
Controlled release formulations of pramipexole
|
|
WO2009137067A1
|
|
Controlled release formulations of alprazolam
|
|
EP2363113A1
|
|
Enhanced immediate release formulations of topiramate
|
|
AU2007319141A1
|
|
Sustained-release formulations of topiramate
|
